Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From MentiNova Inc.
Tech Transfer Roundup: Mustang, Nationwide Children’s Hospital Collaborate In Pediatric Glioblastoma
Partnership will test Mustang’s MB-101 with a second-generation oncolytic HSV-1 virus for potential in treating brain cancer. Canadian biotech launched by CCAB to fight the same cancer.
For the past 50 years, levodopa, a dopamine precursor, has been the gold-standard treatment for people with Parkinson’s disease-, but there is a significant downside---a condition known as L-dopa-induced dyskinesia that emerges after using this medication for some time. MentiNova Inc., a clinical-stage, New Jersey-based biotechnology company, is repurposing the analgesic nalbuphine for the treatment of LID.
Parkinson’s disease remains a significant undermet, attractive opportunity for drug developers, including early-stage biotechs. Profiles of MentiNova, Parkure and Prexton Therapeutics.
This Month's Profile Group, Parkinson’s Disease: Start-Ups Seek Breakthroughs And Money, features profiles of MentiNova, Parkure and Prexton Therapeutics. Plus these Start-Ups Across Health Care: Apifix, Monopar Therapeutics, MitoGenetics, Preora Diagnostics, and Viking Therapeutics.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.